AU2017241904A1 - Formulations for treating constipation - Google Patents
Formulations for treating constipation Download PDFInfo
- Publication number
- AU2017241904A1 AU2017241904A1 AU2017241904A AU2017241904A AU2017241904A1 AU 2017241904 A1 AU2017241904 A1 AU 2017241904A1 AU 2017241904 A AU2017241904 A AU 2017241904A AU 2017241904 A AU2017241904 A AU 2017241904A AU 2017241904 A1 AU2017241904 A1 AU 2017241904A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- peg
- laxatives
- constipation
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 142
- 206010010774 Constipation Diseases 0.000 title claims abstract description 106
- 238000009472 formulation Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 82
- 239000008141 laxative Substances 0.000 claims abstract description 73
- 235000013305 food Nutrition 0.000 claims abstract description 37
- 230000002475 laxative effect Effects 0.000 claims abstract description 20
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 87
- 235000012041 food component Nutrition 0.000 claims description 86
- 239000005417 food ingredient Substances 0.000 claims description 86
- 229940125722 laxative agent Drugs 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 230000037406 food intake Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 claims description 6
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims description 6
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
- 230000001773 anti-convulsant effect Effects 0.000 claims description 5
- 230000001430 anti-depressive effect Effects 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 229940005513 antidepressants Drugs 0.000 claims description 5
- 229960003965 antiepileptics Drugs 0.000 claims description 5
- 239000000480 calcium channel blocker Substances 0.000 claims description 5
- 235000012054 meals Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000021055 solid food Nutrition 0.000 claims description 5
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 235000021487 ready-to-eat food Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229960000836 amitriptyline Drugs 0.000 claims description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960000503 bisacodyl Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 3
- 229960004166 diltiazem Drugs 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229940018602 docusate Drugs 0.000 claims description 3
- 229960000878 docusate sodium Drugs 0.000 claims description 3
- 229940099198 dulcolax Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 3
- 229960004801 imipramine Drugs 0.000 claims description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960000511 lactulose Drugs 0.000 claims description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 3
- 229960000816 magnesium hydroxide Drugs 0.000 claims description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 3
- 229960001597 nifedipine Drugs 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002085 oxycodone Drugs 0.000 claims description 3
- 229960002036 phenytoin Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229940099212 dilaudid Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 description 34
- 239000011230 binding agent Substances 0.000 description 29
- 239000000796 flavoring agent Substances 0.000 description 15
- 235000019634 flavors Nutrition 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 10
- 244000290333 Vanilla fragrans Species 0.000 description 8
- 235000009499 Vanilla fragrans Nutrition 0.000 description 8
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 8
- 235000019868 cocoa butter Nutrition 0.000 description 7
- 229940110456 cocoa butter Drugs 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000016623 Fragaria vesca Nutrition 0.000 description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 5
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 244000060011 Cocos nucifera Species 0.000 description 4
- 235000013162 Cocos nucifera Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 235000019222 white chocolate Nutrition 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 240000008790 Musa x paradisiaca Species 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005176 gastrointestinal motility Effects 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 235000014571 nuts Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 244000307700 Fragaria vesca Species 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- 241000234295 Musa Species 0.000 description 2
- 241001047198 Scomberomorus semifasciatus Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 235000012467 brownies Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013569 fruit product Nutrition 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008371 vanilla flavor Substances 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
Abstract
Described herein are compositions and methods for treating constipation in an individual. In some embodiments, the composition and method for treating constipation comprises providing an individual with a therapeutic that comprises a food item and a laxative.
Description
BACKGROUND [0002] Constipation is a widespread condition worldwide. Constipation is associated with flatus and intestinal swelling, which causes discomfort and abdominal pain to sufferers.
[0003] There are numerous causes of constipation including medical conditions and iatrogenic constipation resulting from certain prescribed medications.
SUMMARY [0004] Constipation affects millions of people yearly worldwide. The condition is attributed to numerous causes, including certain medical conditions and physiological conditions such as Irritable Bowel Syndrome, GI motility disorders, pregnancy, sedentary lifestyle, and diet. In addition numerous medications are associated with causing constipation as a side-effect.
[0005] Traditional laxative based therapies for constipation do not provide a palatable, convenient, appealing, or easily portable method for treating constipation. As such, traditional laxative based therapies do not provide a mechanism for encouraging individual compliance with the treatment. [0006] Described herein are compositions and methods that overcome short comings in traditional therapies by providing a delivery vehicle for one or more laxatives that provides optimal delivery of the one or more laxatives to the colon in order to optimally treat constipation, and further providing a satisfying experience for the individual ingesting the composition thus promoting compliance with the treatment. In some embodiments, the delivery vehicle is a food based delivery vehicle. [0007] Described herein are compositions and methods for promoting gastrointestinal motility. Chewing is known to promote gastrointestinal motility and as such a food based delivery vehicle of a constipation therapeutic as described herein, in solid form, promotes chewing when ingested and as such promotes gastrointestinal motility.
[0008] Described herein are compositions and methods for treating constipation in an individual.
In some embodiments, the composition and method for treating constipation comprises providing an individual with a therapeutic that comprises a food item.
[0009] Described herein is a method for treating constipation in an individual comprising: providing the individual with a food item comprising one or more food ingredients and one or more laxatives, wherein ingestion of the food item by the individual produces a bowel movement in the
WO 2017/172816
PCT/US2017/024606 individual and thus relieves constipation in the individual. In some embodiments, the food item comprises a shelf-stable packaged solid food item. In some embodiments, the one or more laxatives wherein the one or more laxatives comprises any of dibasic sodium phosphate, magnesium citrate, magnesium hydroxide (milk of magnesia), magnesium sulfate (Epsom salt), monobasic sodium phosphate, sodium biphosphate, lactulose, polyethylene glycol (PEG), vitamin C, dioctyl sulfosuccinate (Docusate), bisacodyl (Dulcolax), castor oil, and sorbitol. In some embodiments, the PEG comprises PEG 3350 in a quantity of 17grams or less. In some embodiments, the one or more food ingredients are mixed together with the one or more laxatives. In some embodiments, the one or more laxatives comprises a coating of the food item. In some embodiments, the bowel movement in the individual is produced within 12 hours of ingestion of the one or more laxatives. In some embodiments, the food item comprises a food bar. In some embodiments, the food item comprises a shake or similar beverage. In some embodiments, the individual uses a medication, a side effect of which is constipation. In some embodiments, the medication comprises an opioid. In some embodiments, the opioid comprises one or more of morphine, codeine, oxycodone, and dilaudid. In some embodiments, the medication comprises an antidepressant. In some embodiments, the antidepressant comprises one or more of amitriptyline and imipramine. In some embodiments, the medication comprises an anticonvulsant. In some embodiments, the anticonvulsant comprises one or more of phenytoin and carbamazepine. In some embodiments, the medication comprises an iron supplement. In some embodiments, the medication comprises a calcium channel blocker. In some embodiments, the calcium channel blocker comprises one or more of diltiazem and nifedipine. In some embodiments, the constipation has lasted for a duration of 24 hours or more. In some embodiments, the food item comprises a meal. [0010] Described herein is a composition comprising: one or more laxatives; one or more food ingredients; wherein the laxative is combined with the one or more food ingredients, and wherein the one or more food ingredients are either of a quantity or of a type such that when the composition is ingested by an individual, the one or more food ingredients will be digested to an extent that the one or more laxatives will be released within a colon of the individual. In some embodiments, the one or more laxatives comprises polyethylene glycol (PEG) 3350. In some embodiments, the PEG 3350 comprises a quantity of 17grams or less. In some embodiments, the one or more food ingredients are mixed together with the one or more laxatives. In some embodiments, the one or more food ingredients comprise a coating of the composition. In some embodiments, a bowel movement in the individual is produced within 12 hours of ingestion of the composition. In some embodiments, the composition comprises a ready to eat food bar. In some embodiments, the composition comprises a ready to drink shake. In some embodiments, the
WO 2017/172816
PCT/US2017/024606 composition comprises an edible powder configured to be mixed with a liquid. In some embodiments, the composition comprises a meal. In some embodiments, the one or more laxatives are 50% or greater by weight of a total weight of the composition.
DETAILED DESCRIPTION [0011] Described herein are compositions and methods for treating constipation in an individual. Compositions for treating constipation [0012] Described herein are compositions for treating constipation in an individual comprising a food item.
[0013] In some embodiments, the food item comprises any solid or liquid food item. A solid or liquid food item may comprise a discrete food item or a meal. Non-limiting examples of solid food items include food bars, baked goods, meat products, fruit and fruit products, vegetables and plant based products, candies, gums, nuts and nut products. Non-limiting examples of liquid food items include shakes, sodas, milks, coffees, teas, and flavored water based drinks.
[0014] In some embodiments, the food item comprises food ingredients that may comprise any edible food ingredients used to make a food item. In some embodiments, the food item comprises one or more ingredients that comply with the standards of the National Formulary of the U.S. Pharmacopeial Convention (USP-NF). Non-limiting examples of ingredients include sugars and natural sweeteners, artificial sweeteners, grain based flour, non-grain based flour, fruit and fruit products, vegetables and vegetable products, dairy products including milk, cream, cheese, and butter, edible oils, chocolate, and nuts.
[0015] A food item as described herein comprises one or more food ingredients combined with one or more laxatives. Non-limiting examples of laxatives suitable for combination with the one or more food ingredients include dibasic sodium phosphate, magnesium citrate, magnesium hydroxide (milk of magnesia), magnesium sulfate (Epsom salt), monobasic sodium phosphate, sodium biphosphate, lactulose, polyethylene glycol (PEG) (including, for example, PEG 3350, PEG 4000, PEG 6000, and PEG 8000), vitamin C, dioctyl sulfosuccinate (Docusate), bisacodyl (Dulcolax), castor oil, and sorbitol.
[0016] In some embodiments, one or more food ingredients and one or more laxatives are combined so that the laxative is incorporated inside of the food item. For example, in some embodiments, the food item comprises a food bar and one or more laxatives are incorporated within the food bar. In some embodiments, one or more food ingredients are mixed together with one or more laxatives to form the food item. In some embodiments, the one or more food ingredients and the one or more laxatives form a homogenous mixture. In some embodiments, the one or more food ingredients and one or more laxatives do not comprise a homogenous mixture.
WO 2017/172816
PCT/US2017/024606 [0017] In some embodiments, one or more laxatives comprise one or more agglomerated collections of laxative that are at least partially surrounded by one or more food ingredients. For example, in some embodiments, a single agglomerated quantity of PEG 3350 is surrounded by one or more food ingredients of a baked good such as a brownie so that the agglomerated quantity of PEG 3350 is incorporated within the brownie which comprises the food item. In some embodiments, one or more laxatives comprises a coating of an agglomerated quantity of food ingredients. For example, in some embodiments, a food item comprises a bar with a coating comprising of one or more laxatives. In some embodiments, a coating comprises an icing, frosting, or fondant.
[0018] In some embodiments, a laxative combined with one or more food ingredients comprises PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 130 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 120 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 110 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 100 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 90 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 80 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 70 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 60 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 50 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 40 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 30 grams of PEG 3350.In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 20 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 19 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 18 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 17 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 16 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 15 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 14
WO 2017/172816
PCT/US2017/024606 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 13 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 12 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 11 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 10 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 9 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 8 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 7 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 6 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 5 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 9 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 8 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 7 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 6 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 5 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 4 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 3 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 2 grams of PEG 3350. In some embodiments, the quantity of PEG 3350 combined with one or more food ingredients comprises 1 grams of PEG 3350.
[0019] In some embodiments, a composition for treating composition comprises 40% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 45% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 50% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 55% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 60% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 65% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 70% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 75% or greater laxative
WO 2017/172816
PCT/US2017/024606 by weight. In some embodiments, a composition for treating composition comprises 80% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 85% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 90% or greater laxative by weight. In some embodiments, a composition for treating composition comprises 95% or greater laxative by weight.
[0020] In some embodiments, the location of delivery of the therapeutic agent for treating constipation within the gastrointestinal tract is related to the rate of digestion of the composition in which the therapeutic is incorporated. For example, a composition comprising a thin edible layer takes relatively less time to digest and is digested in the proximal part of the intestinal tract releasing the therapeutic agent for treating constipation in the proximal part of the intestinal tract. For example, a composition comprising a thick edible layer takes relatively more time to digest and is digested in the distal portion of the digestive tract. Thus, by, for example, controlling the thickness of the composition, a point of release of the therapeutic agent for treating constipation within the gastrointestinal tract is controlled. Similarly, in some embodiments, the composition comprises ingredients that are digested in the proximal portion of the gastrointestinal tract, and in some embodiments, the composition comprises ingredients that are digested in the distal portion of the gastrointestinal tract.
[0021] Table 1 below shows a formulation for an exemplary composition for treating constipation comprising a lemon bar.
Table 1
Lemon Bar Ingredient | % by weight | Amount per Unit (grams) 24.4 |
Polyethylene Glycol 3350 | 69.8% | 17.023 |
Invert Syrup | 17.0% | 4.142 |
Cocoa Butter | 12.4% | 3.018 |
Flavor, Milky Vanilla N&A #2713, David Michael | 0.7% | 0.171 |
Citric Acid | 0.1% | 0.029 |
Lemon Oil | 0.1% | 0.016 |
100.0% | 24.400 |
[0022] As shown in table 1, a lemon bar comprises 69.8% by weight PEG 3350 with a total amount of PEG of 17.023 grams. One or more food ingredients include invert syrup, cocoa butter, vanilla, citric acid, and lemon oil. In some embodiments, one or more ingredients are USP-NF grade [0023] Table 2 below shows a formulation for an exemplary composition for treating constipation comprising a white chocolate bar.
WO 2017/172816
PCT/US2017/024606
Table 2
White Chocolate Bar ingredient | % by weight | Amount per Unit (grams) 24.4 |
Poiyethyiene Gfyeoi 3350 | 69.767% | 17,023 |
invert Syrup | 16.772% | 4.092 |
Cocoa Butter | 11.860% | 2.894 |
Flavor, Milky Vanilla N&A #2713, David Michael | 0.700% | 0.171 |
Flavor, Chocolate N&A #50083, David Michael | 0.800% | 0.195 |
Flavor, Creamy Vanilia O.S. #50043, David Michael | 0.100% | 0,024 |
100.000% | 24,400 |
[0024] As shown in table 2, a white chocolate bar comprises 69.767% by weight PEG 3350 with a total amount of PEG of 17.023 grams. One or more food ingredients include invert syrup, cocoa butter, vanilla, and chocolate flavor. In some embodiments, one or more ingredients are USP-NF grade.
[0025] Table 3 below shows a formulation for an exemplary composition for treating constipation comprising a white chocolate bar.
Table 3
Coconut Bar ingredient | % by weight | Amount per Unit (grams) 24.4 |
Poiyethyiene Glyco! 3350 | 69.767% | 17.023 |
Invert Syrup | 16.915% | 4.127 |
Cocoa Butter | 12.267% | 2.993 |
Flavor, Coconut #3728, David Michael | 0.800% | 0.195 |
Flavor, Creamy Vaniiia O.S. #50043, David Michael | 0.250% | 0.061 |
100.000% | 24.400 |
[0026] As shown in table 3, a coconut bar comprises 69.767% by weight PEG 3350 with a total amount of PEG of 17.023 grams. One or more food ingredients include invert syrup, cocoa butter, vanilla, and coconut flavor. In some embodiments, one or more ingredients are USP-NF grade. [0027] Table 4 below shows a formulation for an exemplary composition for treating constipation comprising a strawberry banana shake.
WO 2017/172816
PCT/US2017/024606
Table 4
Strawberry Banana Beverage ingredient | % by weight | Amount per Unit (grams) 122.0 |
Polyethylene Glycol, 3350 (powder) | 94.2623% | 115.00 |
Sucrose, granulated USP | 5.2018% | 6.35 |
Flavor, Strawberry Banana N&A #3620, David Michael | 0.4172% | 0.51 |
Citric acid, USP | 0.1188% | 0.14 |
100.000% | 122.0 |
[0028] As shown in table 4, a strawberry banana shake comprises 94.2623% by weight PEG 3350 with a total amount of PEG of 115.0 grams. One or more food ingredients include EiSP-NF sucrose, strawberry banana flavor, and EiSP-NF citric acid.
[0029] Table 5 below shows a formulation for an exemplary composition for treating constipation comprising a vanilla beverage.
Table 5
Vanilia Beverage ingredient | % by weight | Amount per Unit (grams) 120 |
Polyethylene Glycol, 3350 (powder) | 95.833% | 115.00 |
Sucrose, granulated USP | 2.500% | 3.00 |
Flavor, Milky Vanilla N&A #2713, David Michael | 1.667% | 2.00 |
100.000% | 120.0 |
[0030] As shown in table 5, a vanilla beverage comprises 95.833% by weight PEG 3350 with a total amount of PEG of 115.0 grams. One or more food ingredients include EiSP-NF sucrose and vanilla flavor.
[0031] In some embodiments, the compositions described herein comprise portable ready to eat food items.
[0032] Non-limiting examples of flavors suitable for use in the compositions described herein include sweet flavors, savory flavors, spicy flavors, and sour flavors.
Constipation treatment [0033] In some embodiments, the compositions and methods described herein are used to treat individual suffering from constipation. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a disease process such as, for example, Irritable Bowel Syndrome. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a disease process such as an anxiety disorder. In some embodiments, the constipation treated by the compositions and methods described herein is caused by aging. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a wasting disease such as certain cancers. In some embodiments, the constipation treated by the compositions and methods described herein is caused by poor nutrition.
WO 2017/172816
PCT/US2017/024606
In some embodiments, the constipation treated by the compositions and methods described herein is caused by a medication. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an opioid. In some embodiments, the constipation treated by the compositions and methods described herein is caused by codeine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by oxycodone. In some embodiments, the constipation treated by the compositions and methods described herein is caused by hydromorphone. In some embodiments, the constipation treated by the compositions and methods described herein is caused by buprenoprhine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by fentanyl. In some embodiments, the constipation treated by the compositions and methods described herein is caused by hydrocodone. In some embodiments, the constipation treated by the compositions and methods described herein is caused by meperidine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by methadone. In some embodiments, the constipation treated by the compositions and methods described herein is caused by morphine sulfate. In some embodiments, the constipation treated by the compositions and methods described herein is caused by oxymorphone. In some embodiments, the constipation treated by the compositions and methods described herein is caused by tramadol. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an antidepressant. In some embodiments, the constipation treated by the compositions and methods described herein is caused by amitriptyline. In some embodiments, the constipation treated by the compositions and methods described herein is caused by imipramine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by doxepin. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an antihypertensive. In some embodiments, the constipation treated by the compositions and methods described herein is caused by clonidine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a beta blocker. In some embodiments, the constipation treated by the compositions and methods described herein is caused by atenolol. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an anti-Parkinson’s agent. In some embodiments, the constipation treated by the compositions and methods described herein is caused by bromocriptine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a cholesterol lowering agent. In some embodiments, the constipation treated by the compositions and methods described herein is caused by cholestyramine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a
WO 2017/172816
PCT/US2017/024606 medication for treatment of gastrointestinal ulcers. In some embodiments, the constipation treated by the compositions and methods described herein is caused by sucralfate. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an anticonvulsant. In some embodiments, the constipation treated by the compositions and methods described herein is caused by phenytoin. In some embodiments, the constipation treated by the compositions and methods described herein is caused by carbamazapine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an iron supplement. In some embodiments, the constipation treated by the compositions and methods described herein is caused by a calcium channel blocker. In some embodiments, the constipation treated by the compositions and methods described herein is caused by diltiazem. In some embodiments, the constipation treated by the compositions and methods described herein is caused by nifedipine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an NSAID. In some embodiments, the constipation treated by the compositions and methods described herein is caused by ibuprofen. In some embodiments, the constipation treated by the compositions and methods described herein is caused by an anticholinergic. In some embodiments, the constipation treated by the compositions and methods described herein is caused by diphenhydramine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by cetirizine. In some embodiments, the constipation treated by the compositions and methods described herein is caused by fexofenadine. [0034] In some embodiments, a method for treating constipation in an individual comprises providing the individual with a composition comprising one or more food ingredients and one or more laxatives as described herein, and wherein the formulation of the composition is such that ingestion of the composition by the individual causes a bowel movement in the individual. Manufacture [0035] Non-limiting examples of processes for assembling a food item as described herein include mixing, cooking, and baking one or more food ingredients and/or one or more laxatives.
[0036] When the one or more food ingredients and/or the one or more laxatives are heated in order to manufacture the food item, the heating is done at a temperature wherein the food ingredients tend to coalesce together while the laxatives remain unchanged. In some embodiments, neither the one or more food ingredients coalesce nor are the one or more laxatives changed. In some embodiments, the one or more food ingredients and the one or more laxatives all coalesce together when heated. Typically, heat is not applied at or above a temperature at which a therapeutic property of one or more laxatives of the compound are affected.
WO 2017/172816
PCT/US2017/024606 [0037] The effect of heating is determined by both the temperature and duration over which heat is applied. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 350 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 300 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 250 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 200 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 150 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 100 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 95 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 90 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 85 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 80 degrees Fahrenheit. In some embodiments, a compound for treating constipation comprises a mixture of one or more laxatives and one or more food ingredients which are heated to a temperature at or above 75 degrees Fahrenheit. In some embodiments, the duration of heating is 1 hour or greater.
In some embodiments, the duration of heating is 45 minutes or greater. In some embodiments, the duration of heating is 30 minutes or greater. In some embodiments, the duration of heating is 20 minutes or greater. In some embodiments, the duration of heating is 15 minutes or greater. In some embodiments, the duration of heating is 10 minutes or greater. In some embodiments, the duration of heating is 5 minutes or greater. In some embodiments, the duration of heating is 1 minute or greater.
[0038] In some embodiments, a compound for treating constipation further comprises a binder, wherein a binder is an element used to bind one or more elements of the compound together. In
WO 2017/172816
PCT/US2017/024606 some embodiments, the binder is edible. In some embodiments, the binder comprises cocoa butter. In some embodiments, the binder comprises coconut oil.
[0039] In some embodiments, a binder is heated and the elements of the compound are added to the heated binder. In some embodiments, one or more elements of the compound are added to the binder at the hottest temperature to which it is heated. In some embodiments, one or more elements of the compound are added to the heated binder after it has cooled. In some embodiments, the binder is a liquid when heated so that when mixed with the elements of the compound, the elements coalesce or are “bound” together by the binder. In an exemplary embodiment, a binder in the compound is in a solid state at room temperature and a liquid state at a relatively small increase in temperature above room temperature. This exemplary binder is used in binding the elements of the compound when a solid compound is used such as, for example, a bar. In the liquid state the binder can coalesce the elements, and, as stated, the exemplary binder is in a liquid state at temperatures slightly above room temperature, thus the other elements of the compound are not heated due to the binder to a large extent which is especially important with respect to the laxatives that are damaged at high temperatures. In some embodiments, a binder is heated to a temperature at or above 95 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, a binder is heated to a temperature at or above 90 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, a binder is heated to a temperature at or above 85 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, a binder is heated to a temperature at or above 80 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, a binder is heated to a temperature at or above 75 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, a binder is heated to a temperature at or above 70 degrees Fahrenheit and then one or more elements of the compound for treating constipation are mixed together with it. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 30 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 25 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 20 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 15
WO 2017/172816
PCT/US2017/024606 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 10 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. In some embodiments, after being heated to an initial temperature, the binder is allowed to cool 5 degrees from the initial temperature before one or more elements of the compound for treating constipation are added. It is understood that numerous other edible binders are suited, non-limiting examples of which include lard, vegetable shortening, palm oil, butter, or margarine.
[0040] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
WO 2017/172816
PCT/US2017/024606
Claims (33)
- WHAT IS CLAIMED IS:1. A method for treating constipation in an individual comprising:providing the individual with a food item comprising one or more food ingredients and one or more laxatives, wherein ingestion of the food item by the individual produces a bowel movement in the individual and thus relieves constipation in the individual;wherein the food item comprises a shelf-stable packaged solid food item.
- 2. The method of claim 1, wherein the one or more laxatives comprises any of dibasic sodium phosphate, magnesium citrate, magnesium hydroxide (milk of magnesia), magnesium sulfate (Epsom salt), monobasic sodium phosphate, sodium biphosphate, lactulose, polyethylene glycol (PEG), vitamin C, dioctyl sulfosuccinate (Docusate), bisacodyl (Dulcolax), castor oil, and sorbitol.
- 3. The method of claim 2, wherein the PEG comprises PEG 3350 in a quantity of 17grams or less.
- 4. The method of claim 1, wherein the one or more food ingredients are mixed together with the one or more laxatives.
- 5. The method of claim 1, wherein the one or more laxatives comprises a coating of the food item.
- 6. The method of claim 1, wherein the bowel movement in the individual is produced within 12 hours of ingestion of the one or more laxatives.
- 7. The method of claim 1, wherein the bowel movement in the individual is produced within 24 hours.
- 8. The method of claim 1, wherein the food item comprises a ready to eat food bar.
- 9. The method of claim 1, wherein the food item comprises an edible powder either with or without flavoring and configured to be mixed with a liquid.
- 10. The method of claim 1, wherein the individual uses a medication, a side effect of which is constipation.
- 11. The method of claim 10, wherein the medication comprises an opioid.
- 12. The method of claim 11, wherein the opioid comprises one or more of morphine, codeine, oxycodone, and dilaudid.
- 13. The method of claim 10, wherein the medication comprises an antidepressant
- 14. The method of claim 13, wherein the antidepressant comprises one or more of amitriptyline and imipramine.WO 2017/172816PCT/US2017/024606
- 15. The method of claim 10, wherein the medication comprises an anticonvulsant.
- 16. The method of claim 15, wherein the anticonvulsant comprises one or more of phenytoin and carbamazepine.
- 17. The method of claim 10, wherein the medication comprises an iron supplement.
- 18. The method of claim 10, wherein the medication comprises a calcium channel blocker.
- 19. The method of claim 18, wherein the calcium channel blocker comprises one or more diltiazem and nifedipine.
- 20. The method of claim 1, wherein the constipation has lasted for a duration of 24 hours or more.
- 21. The method of claim 1, wherein the food item comprises a meal.
- 22. The method of claim 1, wherein the one or more laxatives are 50% or greater by weight of a total weight of the food item.
- 23. A composition comprising:one or more laxatives; one or more food ingredients;wherein the laxative is combined with the one or more food ingredients, and wherein the one or more food ingredients are either of a quantity or of a type such that when the composition is ingested by an individual, the one or more food ingredients will be digested to an extent that the one or more laxatives will be released within a colon of the individual.
- 24. The composition of claim 23, wherein the one or more laxatives comprises polyethylene glycol (PEG) 3350.
- 25. The composition of claim 23, wherein the PEG 3350 comprises a quantity of 17grams or less.
- 26. The composition of claim 23, wherein the one or more food ingredients are mixed together with the one or more laxatives.
- 27. The composition of claim 23, wherein the one or more food ingredients comprise a coating of the composition.
- 28. The composition of claim 23, wherein a bowel movement in the individual is produced within 12 hours of ingestion of the composition.
- 29. The composition of claim 23, wherein the composition comprises a ready to eat food bar.
- 30. The composition of claim 23, wherein the composition comprises a ready to drink shake.
- 31. The composition of claim 23, wherein the composition comprises an edible powder configured to be mixed with a liquid.
- 32. The composition of claim 23, wherein the composition comprises a meal.WO 2017/172816PCT/US2017/024606
- 33. The composition of claim 23, wherein the one or more laxatives are 50% or greater by weight of a total weight of the composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314883P | 2016-03-29 | 2016-03-29 | |
US62/314,883 | 2016-03-29 | ||
PCT/US2017/024606 WO2017172816A1 (en) | 2016-03-29 | 2017-03-28 | Formulations for treating constipation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2017241904A1 true AU2017241904A1 (en) | 2018-10-18 |
Family
ID=59966423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017241904A Abandoned AU2017241904A1 (en) | 2016-03-29 | 2017-03-28 | Formulations for treating constipation |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3436011A4 (en) |
JP (1) | JP2019513355A (en) |
KR (1) | KR20180123136A (en) |
CN (1) | CN109475544A (en) |
AU (1) | AU2017241904A1 (en) |
CA (1) | CA3018589A1 (en) |
IL (1) | IL261958A (en) |
WO (1) | WO2017172816A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200383934A1 (en) * | 2018-01-12 | 2020-12-10 | Colonaryconcepts Llc | Constipation specific treatment formulations |
US20200360423A1 (en) * | 2018-01-12 | 2020-11-19 | Colonaryconcepts Llc | Solid concentrated constipation treatment formulations |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232699A (en) * | 1990-07-26 | 1993-08-03 | The Proctor & Gamble Company | Laxative compositions |
US5234916A (en) * | 1992-06-12 | 1993-08-10 | The Proctor & Gamble Company | Psyllium drink mix compositions |
TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
CA2546019A1 (en) * | 2003-11-17 | 2005-06-02 | Braintree Laboratories, Inc. | Therapeutic peg solution concentrate |
AU2006244112B2 (en) * | 2005-05-06 | 2011-02-17 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
CN101002832B (en) * | 2006-09-02 | 2011-01-05 | 江西农业大学 | Granulated quickly dissolving medicine for relaxing bowel |
CN101589806A (en) * | 2008-05-29 | 2009-12-02 | 北京亿利高科生物工程技术研究所有限公司 | A kind of solid low-energy food that is rich in dietary fiber and polyethylene glycol and preparation method thereof |
US9655919B2 (en) * | 2008-07-09 | 2017-05-23 | The General Hospital Corporation | Methods and compositions for bowel cleansing before a medical procedure |
US20120107430A1 (en) * | 2009-05-01 | 2012-05-03 | Jeffery Dale Scott | Pre-procedure meal regimen |
WO2013067424A1 (en) * | 2011-11-06 | 2013-05-10 | Ssv Therapeutics, Llc | Formulations of concentrated prunes and prebiotics as laxatives and dietary supplements |
WO2013096444A1 (en) * | 2011-12-19 | 2013-06-27 | Salix Pharmaceuticals, Ltd. | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
CN104837503B (en) * | 2012-08-21 | 2018-11-09 | 阿德利克斯公司 | Treating the Compounds and methods for that the antiport in relevant disease and enterogastric diseases being used to that NHE- to be inhibited to mediate is overloaded with fluid retention or salinity |
WO2014032108A1 (en) * | 2012-08-29 | 2014-03-06 | Borody Thomas J | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
BR112016025481A2 (en) * | 2014-04-29 | 2017-08-15 | Colonaryconcepts Llc | Foods, Systems, Methods and Cases for Electrolyte Replacement Provision |
AU2016315848A1 (en) * | 2015-09-01 | 2018-04-12 | Colonaryconcepts Llc | Laxative formulations and manufacture |
-
2017
- 2017-03-28 CA CA3018589A patent/CA3018589A1/en not_active Abandoned
- 2017-03-28 CN CN201780033365.6A patent/CN109475544A/en active Pending
- 2017-03-28 JP JP2018549545A patent/JP2019513355A/en active Pending
- 2017-03-28 AU AU2017241904A patent/AU2017241904A1/en not_active Abandoned
- 2017-03-28 WO PCT/US2017/024606 patent/WO2017172816A1/en active Application Filing
- 2017-03-28 KR KR1020187030503A patent/KR20180123136A/en not_active Application Discontinuation
- 2017-03-28 EP EP17776492.5A patent/EP3436011A4/en not_active Withdrawn
-
2018
- 2018-09-26 IL IL261958A patent/IL261958A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3436011A4 (en) | 2019-12-04 |
IL261958A (en) | 2018-10-31 |
EP3436011A1 (en) | 2019-02-06 |
CN109475544A (en) | 2019-03-15 |
CA3018589A1 (en) | 2017-10-05 |
KR20180123136A (en) | 2018-11-14 |
WO2017172816A1 (en) | 2017-10-05 |
JP2019513355A (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101465836B1 (en) | Granular jelly beverage for medication and process for producing the same | |
KR101827026B1 (en) | Methods and compositions for inducing satiety | |
KR20040105737A (en) | Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions | |
WO2005025622A1 (en) | Bitterness-masking particulate jelly beverage | |
WO2007044663A1 (en) | Compositions and methods for inducing satiety and reducing caloric intake | |
JPH07242539A (en) | Composition having laxative effect | |
AU2017241904A1 (en) | Formulations for treating constipation | |
JP3462535B2 (en) | Mineral absorption promoting composition | |
KR20180041230A (en) | Laxative formulation and manufacture | |
KR100877050B1 (en) | A method of producing sugar-free syrup of low calories | |
JP6037595B2 (en) | Satiety induction composition and method for producing the same | |
US20230158062A1 (en) | Formulations for treating constipation | |
US20020110531A1 (en) | Cholesterol reducing composition and method of making the same | |
JP3240345B2 (en) | Oral hypnotics, hypnotic foods and drinks | |
JP2013508338A (en) | Use of an extract derived from Salumum Glaucophyllum for the treatment of bone metabolism disorders and kidney disorders | |
US20200360423A1 (en) | Solid concentrated constipation treatment formulations | |
JP4207477B2 (en) | Composition for improving bowel movement | |
TWI530256B (en) | Method for producing anti-mental fatigue agent utilizing ferro-bound lactoferrin | |
CN113573593A (en) | Ice cream rich in protein | |
WO2008080810A2 (en) | Composition comprising cocoa fibre | |
JP2003230360A (en) | Ice cream having health enhancement effect and beauty/ diet effect, and method for producing the same | |
JPH11289973A (en) | Processed food obtained by mixing dried powder or the like of curcumae rhizoma with drinking milk | |
JP2001299242A (en) | Food containing gelling agent and method for producing the same | |
RU2582825C1 (en) | Method for production of functional purpose ice cream | |
JPH1146720A (en) | Nutritive composition for promoting absorption of calcium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |